PLx Pharma is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products. The PLxGuard™ drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx Pharma believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.
We believe our PLxGuard™ drug delivery platform may have the potential to…
- Enhance delivery of active pharmaceutical ingredients
- Reduce risk of stomach erosions and ulcers
- Provide new or extended patent protection for an already-approved or development-stage drugs
- Utilize the 505(b)(2) New Drug Application (NDA) regulatory path that often provides a faster and lower cost FDA approval when used with already-approved drugs
The PLxGuard delivery system has clinically shown these benefits with its novel formulation using aspirin.1* And, there is clinical data for ibuprofen and pre-clinical data for oral diclofenac and intravenous indomethacin products suggesting the potential to demonstrate similar benefits. Other existing or new drugs in development that may benefit from the PLxGuard delivery system will be evaluated either by us or through collaboration agreements with other companies.
*At 7 days versus immediate release aspirin tablets. (See Cryer, et al)